Pfizer is planning a major expansion of its research and development facilities in Pearl River, according to company officials.

The pharmaceutical and biotechnology giant will invest $470 million to build a new vaccine R&D building on its existing campus as well as upgrade existing facilities there.

Pearl River is where much of the development of the company's COVID-19 vaccine took place.

Company officials say that given the success of that vaccine, Pfizer (PFE) is aiming to expand mRNA technology for use in other diseases.

The 260,000-square-foot expansion that includes 55,000-square feet of laboratories should be completed in the beginning of 2026.